Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient

NACompletedINTERVENTIONAL
Enrollment

552

Participants

Timeline

Start Date

November 15, 2017

Primary Completion Date

June 18, 2021

Study Completion Date

August 18, 2021

Conditions
Infertility
Interventions
DRUG

Follitropin Beta;MSD

Patients will start stimulation with a daily s.c. injection of follitropin beta( 300IU Puregonon;MSD) menstrual cycle day 2 or 3.

DRUG

Ganirelix

A daily administration of ganirelix (0.25 mg Orgalutran; MSD) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.

DRUG

hCG

Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger

DRUG

estradiol valerate

Estradiol valerate (progynova,Schering) daily dose of 4 mg (2 mg twice a day) was given orally, started 7 days before the presumed onset of menses and administered up to 2 days of the next menstrual cycle

Trial Locations (1)

Unknown

Reproductive & Genetic Hospital of Citic-Xiangya, Changsha

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Reproductive & Genetic Hospital of CITIC-Xiangya

OTHER

NCT03300518 - Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient | Biotech Hunter | Biotech Hunter